Back to Search
Start Over
PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort.
- Source :
-
European Journal of Cancer . Jul2024, Vol. 205, pN.PAG-N.PAG. 1p. - Publication Year :
- 2024
-
Abstract
- Papillary renal cell carcinoma (pRCC) is a rare and aggressive cancer with no specifically established therapeutic strategy in the metastatic setting. Combinations of tyrosine kinase and immune checkpoint inhibitors (ICI) are a promising option. We aimed to study the immune landscape of metastatic pRCC, and its interactions with angiogenesis pathways, to search for potential therapeutic targets. The expression of immune markers (PD-L1, PD-1, PD-L2, LAG-3) and angiogenic pathways (CAIX, c-MET), was analyzed by immunohistochemistry on 68 metastatic pRCC retrieved from a retrospective multicenter GETUG cohort. Our primary endpoint was to estimate the prevalence of PD-L1 expression and its prognostic impact in metastatic pRCC. Secondary endpoints included the evaluation of other immune markers (PD-1, PD-L2, and LAG-3) and their association with PD-L1. We also assessed angiogenic markers and their association with PD-L1. Overall, 27.9 % of tumors were PD-L1 positive. PD-L2 was more frequently expressed (45.6 %), PD-1 and LAG-3 were positive in 17.6 % and 19.1 % respectively. None of these markers was correlated with PD-L1 expression. 66 % (45/68) expressed at least one immune marker, and 43 % (29/68) were "double-positive", as they expressed both immune and angiogenic markers. OS was significantly shorter for patients with PD-L1 positive pRCC. A multivariate analysis confirmed a significant association between PD-L1 expression and shorter overall survival (HR = 4.0, p = 0.01). These results reinforce clinical data on the expected benefit of ICI in metastatic pRCC treatment, as PD-L1 expression is a factor of poor prognosis in this multicenter cohort. • 28 % of the 68 metastatic papillary renal cell carcinoma (pRCC) were PD-L1 positive. • pRCC expressing PD-L1 had a poorer metastatic overall survival. • 43 % of the pRCC were "double positive", expressing immune and angiogenic markers. [ABSTRACT FROM AUTHOR]
- Subjects :
- *THERAPEUTIC use of antineoplastic agents
*STATISTICAL correlation
*CANCER invasiveness
*PROGRAMMED death-ligand 1
*PAPILLARY carcinoma
*RARE diseases
*TUMOR markers
*RETROSPECTIVE studies
*DISEASE prevalence
*MULTIVARIATE analysis
*NEOVASCULARIZATION inhibitors
*GENE expression
*METASTASIS
*IMMUNE checkpoint inhibitors
*IMMUNOHISTOCHEMISTRY
*RENAL cell carcinoma
*RESEARCH
*PROTEIN-tyrosine kinases
*SURVIVAL analysis (Biometry)
*PATHOLOGIC neovascularization
*IMMUNITY
*OVERALL survival
*PHARMACODYNAMICS
Subjects
Details
- Language :
- English
- ISSN :
- 09598049
- Volume :
- 205
- Database :
- Academic Search Index
- Journal :
- European Journal of Cancer
- Publication Type :
- Academic Journal
- Accession number :
- 177651844
- Full Text :
- https://doi.org/10.1016/j.ejca.2024.114121